The secondary immunogenicity endpoints

had the same definitions, but the MN assay was used in a subset of 33% randomly selected samples. Safety endpoints were divided into localized irritation (injection-site pain, erythema and swelling) and systemic reactions (fever, fatigue, headaches and anorexia). They were self-recorded in diaries for 7 days post-immunization. All serious adverse events (SAEs) were actively searched for and if present followed up until their resolution; recording selleck chemical stopped on 28 February 2010 when the study was officially concluded. The potential influence of the vaccine on the underlying disease activity was also evaluated. HIV RNA levels were measured prior to the first and 4 weeks after the second vaccination in 2009; in 2010 these measurements were performed before and 4 weeks after the single immunization. Individuals with elevated post-immunization HIV RNA levels were contacted for a subsequent HIV RNA determination as part of standard care. Quantitative plasma HIV-1 Olaparib concentration RNA (viral load) was measured on a Roche COBAS TaqMan HIV-1 test version 2.0 (COBAS AmpliPrep; Roche Diagnostic, Basel, Switzerland). A significant increase in viral load was defined

as either any detectable HIV RNA in previously aviraemic patients or an increase of ≥1 log10 copies/mL in individuals with detectable baseline HIV RNA levels. As a consequence of

the lack of conclusive data concerning the immunogenicity of AS03-adjuvanted influenza A/09/H1N1 vaccines at the time of the study design, sample size was based on our single-centre recruitment capacity. Differences in antibody titres between groups were described by the GMT and corresponding 95% confidence interval. The reverse cumulative distributions were obtained by plotting antibody levels on a logarithmic scale on the horizontal axis and the percentage of subjects 3-mercaptopyruvate sulfurtransferase having attained at least that level of antibody on the vertical axis. The comparison of titres between individual strata of categorical variables was assessed by means of the Kruskal–Wallis test. The association between continuous factors and antibody titre was described using the Spearman correlation coefficient. Multivariate regression models were constructed to investigate the association between specific independent variables and post-vaccination antibody titres. Variables with a P-value of <0.25 in the univariate analysis were introduced to the multivariate regression model. As the distribution of titres was not Gaussian, data were logarithmically transformed prior to analysis. The normality of the residuals was confirmed using the Shapiro–Wilks test.